Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Chiara Agrati1,2, Concetta Castilletti1,2, Delia Goletti3, Alessandra Sacchi3, Veronica Bordoni3, Davide Mariotti2, Stefania Notari2, Giulia Matusali1, Silvia Meschi1, Linda Petrone1, Alessandra Aiello1, Saeid Najafi Fard1, Chiara Farroni2, Francesca Colavita1, Daniele Lapa3, Sara Leone1, Alessandro Agresta1, Maria Capobianchi2, Giuseppe Ippolito1,2*, Francesco Vaia1, Vincenzo Puro1 & INMI COVID-19 Vaccine Study Group*

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlights its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.

Large-scale vaccination is the single most effective public health measure for mitigation of the coronavirus disease (COVID-19) pandemic and a global effort to develop and distribute an effective vaccine produced several effective options.

Several data are currently available about the effectiveness of BNT162b2 (two-dose vaccination regimen administered 21 days apart) in inducing a strong antibody and cell-mediated immune response in healthy individuals with a 95% efficacy in naïve individuals1–3. Moreover, the coordinate induction of both humoral- and cell-mediated arms has been clearly demonstrated more effective in fighting SARS-CoV-2 infection4,5.

The persistence of a specific immune response represents a crucial point to be addressed in order to define the risk of re-infection and to optimize the vaccination strategies. In convalescent patients, several data confirmed that both antibodies and T cell response persisted 6–8 months after the infection5,6 but no definitive data are available in vaccinated individuals.

In this study, we established the dynamics and persistence of the immune response by assessing the both anti-Region-Binding-Domain (RBD) antibody and Spike (S)-specific T-cell response early and after 12 weeks from vaccination in a cohort of HCWs who received a two-dose BNT162b2-mRNA vaccination at the National Institute for Infectious Diseases L. Spallanzani in Rome.

1INMI L. Spallanzani–IRCCS, Via Portuense 292, 00149 Rome, Italy. 2These authors contributed equally: Chiara Agrati and Concetta Castilletti. *A list of authors and their affiliations appears at the end of the paper. *email: giuseppe. ippolito@inmi.it
Methods

Enrolled subjects. A convenient sample (n = 78) of HCWs who received BNT162b2 mRNA vaccine were extracted from the cohort of vaccinated HCWs established at the INMI L.Spallanzani. All enrolled HCWs were naive for SARS-CoV-2 infection as shown by a negative test for anti-Nucleocapside (anti-N) and anti-Spike receptor-binding-domain (anti-RBD) antibodies at T0. Out of 78 HCWs enrolled in the study, 58 (74.3%) were women, median age was 45 years (IQR 26–64). Most enrolled HCWs (n = 59, 76%) had been employed in direct care to COVID-19 patients. The study was approved by the Ethical committees of the National Institute for Infectious Diseases L. Spallanzani (issue N. 297/2021) and all HCWs signed an informed consent. All methods were performed in accordance with the relevant guidelines and regulations.

Antibody evaluation and micro-neutralization assay (MNA90). Two commercial chemiluminescence microparticle antibody assays (ARCHITECT® i2000sr Abbott Diagnostics, Chicago, IL, USA) were used: the anti-Nucleoprotein IgG and the SARS-CoV-2 IgG II kit, detecting antibodies against the RBD of SARS-CoV-2. The neutralization assay was performed according to7, using SARS-CoV-2/Human/ITA/PAVIA10734/2020, provided by Fausto Baldanti, Pavia, as challenging virus.

T-cell immune response. Peripheral blood was collected in heparin tubes and stimulated or not with a pool of peptides spanning the Spike protein (Miltenyi Biotech, Germany) at 37 °C (5% CO2), according to8–10. A superantigen (SEB) was used as positive control. Plasma were harvested after 16–20 h of stimulation and stored at −80 °C. Th1-cytokines (IFN-γ, TNF-α, IL-2) were quantified in the plasma samples using an automatic ELISA (ELLA, Protein Simple). The detection limit of these assays were 0.17 pg/ml, 0.3 pg/ml and 0.54 pg/ml for IFN-γ, TNF-α and IL-2 respectively.

Statistical analysis. Continuous variables including anti-RBD, anti-N, MNA90 titers, IFN-γ, TNF-α, IL-2 levels were reported as median and interquartile range (IQR). Comparison of medians across groups were evaluated using Wilcoxon for pairwise comparisons. Correlations between assays were assessed by non-parametric Spearman’s rank tests. Analyses were performed using Graph Pad. A 2-sided P value < 0.05 was considered statistically significant.

Results

We assessed the kinetics of humoral- and cell-mediated immune response to BNT162b2-mRNA vaccination in 78 HCWs. Specifically, the enrolled HCWs were sampled 5 (T5w) and 12 (T12w) weeks after vaccination and humoral response was evaluated by anti-RBD antibody, while the natural infection was excluded by anti-N antibody. As shown in Fig. 1A, anti-N antibodies were undetectable at both time points, confirming no SARS-CoV-2 natural infection during the study duration (Fig. 1A). In contrast, a detectable anti-RBD antibody response was observed in 100% of HCWs early after vaccination (T5w) as previously published10, and persisted in all but one HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination. Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w). Nevertheless, a significant reduction of anti-RBD titer was observed in all HCWs after 12 weeks from vaccination (T12w).

The S-specific T cells was evaluated by quantifying Th1 cytokines (IFN-γ, IL-2 and TNF-α) after stimulation with a pool of peptides covering the S protein (Fig. 1B). All HCW showed a positive specific T cell response and produced IFN-γ (78/78, 100%), IL-2 (78/78, 100%) and TNF-α (72/78, 92.3%). Interestingly, differently from the antibody titer, specific T cells persisted overtime and, although few patients experienced a very slight decrease, the level of IFN-γ (median T5w: 343 pg/ml [IQR: 167–703.6] vs. T12w: 199.1 pg/ml [93.7–437.9], p = 0.13), of IL-2 (median T5w: 177 pg/ml [83.9–305.1] vs. T12w: 156.5 pg/ml [72.3–302.0], p = 0.12) and of TNF-α (median T5w: 62 pg/ml [30.8–312.8], p < 0.002) persisted overtime. In contrast, a decrease of TNF-α production was observed (median T5w: 125 pg/ml [60.3–210.3] vs. T12w: 62 pg/ml [12.3–142.8], p < 0.002), probably due to a strong reduction occurred in 15 HCWs. Not particular features of these 15 patients (age, gender, comorbidity) has been reported.

We therefore focused on the immune response at T12w in order to define the coordination of both humoral and cell-mediated immunity (Fig. 1C). A positive correlation between anti-RBD and MNA90 was maintained (r = 0.5606, p < 0.0001), although decrease respect to that observed early after vaccination (r = 0.8103, p < 0.0001). The S-specific T cell response at T12w was characterized by the production by Th1 cytokines and the amount of IFN-γ correlated with IL-2 (r = 0.6733, p < 0.0001) and TNF-α (r = 0.6733, p < 0.0001). Finally, a slight but significant correlation between anti-RBD antibody and IFN-γ (R = 0.3421, p < 0.0001), IL-2 (r = 0.3441, p < 0.0001) and TNF-α (R = 0.2735, p < 0.0001) has been reported, suggesting the persistence of a coordinated humoral and cell-mediated immune response.

Discussion

The vaccination strategies are aimed to induce a protective immunity with persistent humoral and cell-mediated immune response. In this context, Yellow Fever and smallpox vaccines represent good examples inducing remarkably effective and long-lived immune protection through the induction of neutralizing antibodies and T-cells with broad specificity, high magnitude, polyfunctionality, high proliferative potential and long-term persistence11.

In this study, we described the persistence of both humoral and cell-mediated immune response to Spike in HCW after 12 weeks from vaccination. Nevertheless, while anti-RBD and neutralizing titer decreased overtime, the S-specific T cell immunity persisted at similar level.
Figure 1. (A) Humoral response 5 (T5w) and 12 (T12w) weeks after vaccination. SARS-CoV-2 specific anti-N, anti-RBD and neutralizing Abs were quantified in sera samples at both time points. Anti-N-IgG are expressed as index values S/CO and values ≥ 1.4 are considered positive; Anti-RBD-IgG are expressed as Binding Arbitrary Units (BAU)/mL and values ≥ 7.1 are considered positive; neutralizing Abs are expressed as the highest serum reciprocal of dilution inhibiting at least 90% of the cytopathic effect (MNA90), values ≥ 10 are considered positive. (B) Cell-mediated immune response 5 (T5w) and 12 (T12w) weeks after vaccination. Cytokines (IFN-γ, TNF-α, IL-2) were quantified in stimulated blood samples at both time points and showed after subtracting the background. Dashed line identify the cut-off of each test calculated as the mean ± 2SEM of 55 anti-S and anti-N negative HCW before vaccination. Differences between the median in T5w and T12w were calculated by paired t test. ****p < 0.0001; *p < 0.5. (C) Correlation between humoral and cell-mediated immune response 12 (T12w) weeks after vaccination. Correlations within humoral levels (anti-RBD and MNA90), within cell-mediated response (IFN-γ, TNF-α and IL-2) and across humoral and cell-mediated immunity (anti-RBD and IFN-γ, TNF-α and IL-2) are shown. Correlation was analyzed by Spearman test. Comparison of medians across groups were evaluated by Wilcoxon test for pairwise comparisons. Correlations between assays were assessed by non-parametric Spearman’s rank tests. A 2-sided P value < 0.05 was considered statistically significant.
The ability of BNT162b2 mRNA to induce a strong humoral and cell-mediated immune response early after vaccination was confirmed in several studies1–3 but data on their persistence have not still clarified. In convalescent SARS-CoV-2 patients growing evidences support the persistence of the immune response more than 8 months both in symptomatic and in asymptomatic patients4–6. During the acute phase of infection, the induction of a coordinate immune response, by neutralizing antibodies production and specific T-cell response resulted effective against the virus and represents a main feature of mild disease4,14. After recovery, each component of SARS-CoV-2 immune memory persisted and differentiate in memory cells5.

Here we showed that two dose of BNT162b2 mRNA vaccine in healthy subjects induced a strong anti-RBD and neutralizing antibody response which however begin to decrease after 12 weeks from vaccination prime. The decrease of effector antibody-producing B cells could be associated to the differentiation of the specific memory compartment, as demonstrated after natural infection2. Interestingly, despite the antibody reduction, a persistent T cell immunity has been observed and S-specific T lymphocytes produced IFN-γ and IL-2 at similar extent as early after vaccination, suggesting the maintenance of a robust pool of effector Ag specific T cells until 12 weeks. The ability to respond to specific stimulation producing several Th1 cytokines may represent a good marker of protective phenotype as shown in convalescent COVID-19 patients15. In particular, the production of IL-2 can be essential for the homeostatic maintenance of a functional specific T-cell response. Moreover, we found a positive correlation between the two arms of the immune system that can be important to generate a balanced memory pool of B and T lymphocytes. A reduced level of neutralizing antibody at 6 months post-vaccination as well as memory B and T cells was reported16. Of note, vaccine-induced memory B cells can recognize the variants of concern showing a high hypermutation in variant-binding B cell clones, suggesting a continued evolution to fight new variants.

Overall, our study describes the different kinetic of anti-RBD and Cell-mediated immune response after 12 weeks from BNT162b2 mRNA vaccine in a cohort of HCWs. Despite a significant decrease of antibody, the specific T cells able to produce several Th1 cytokines persisted as early after booster dose to elicit a coordinated neutralizing humoral and cytokine producing S-specific T-cell response in HCW. The study has been conducted in a single center and recruited healthy, young and middle aged adults, predominantly female, without previous SARS-CoV-2 infection, and its findings should not be generalized to different population.

Assessing the dynamics of these parameters is essential to evaluate the long-term protection and to establish its duration. These results will be crucial to generate the evidence needed for a better understanding of the optimal vaccination strategy.

Data availability
The data presented in this study are available on request from the corresponding author.

Received: 22 June 2021; Accepted: 29 November 2021
Published online: 23 April 2022

References
1. Polack, F. F. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383(27), 2603–2615 (2020).
2. Thompson, M. G. et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations, December 2020–March 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 495–500 (2021).
3. Angyal, A. et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously SARS-CoV-2-infected and infection-naive UK healthcare workers: A multicentre, prospective, observational cohort study. SSRN: https://ssrn.com/abstract=3812375 or https://doi.org/10.2139/ssrn.3812375.
4. Modderbacher, C. R. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183(4), 996–1012 (2020).
5. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 371(587), eabf063 (2021).
6. Sherina, N. et al. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection. Med 2(3), 281–295 (2021).
7. Meschi, S. et al. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test. J. Clin. Virol. 129, 104539 (2020).
8. Aiello, A. et al. Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. Int. J. Infect. Dis. 106, 338–347 (2021).
9. Puro, V. Prior influenza and pneumococcal vaccines do not impact on humoral and cellular response to SARS-CoV-2 BNT162b2 vaccination. Vaccines 9, 615 (2021).
10. Agrati, C. et al. Coordinate induction of humoral and Spike specific T-cell response in a cohort of health care workers receiving BNT162b2 mRNA vaccine. Microorganisms 9(6), 1315 (2021).
11. Ahmed, R. & Akondy, R. S. Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines. Immunol. Cell Biol. 89(3), 340–345 (2011).
12. Jiang, X. L. et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. J. Infect. Dis. 12, 897 (2021).
13. Takuya, S. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183(1), 158-168. e14 (2020).
14. Peng, X. et al. Broad and strong memory CD4+ and CD8+ T-cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
15. Goel, R. R. et al. mRNA vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. bioRxiv. https://doi.org/10.1101/2021.08.23.457229 (2021).

Author contributions
Conceptualization: M.R.C., G.I., V.P., C.A., D.G.; Methodology: S.M., A.S., G.M., L.P., S.N., S.F.N., F.C., V.B., A.A., C.F., D.M.; Validation: C.A., D.G.; Vaccination management: F.V.; Formal Analysis: C.A., C.C., D.G;
Data curation: S.N., C.A., C.C., V.B.; Statistical analysis: S.L., A.A., V.P.; Original draft preparation: C.A., D.G., C.C.; Review and editing: M.R.C., G.I., F.V., V.P.; Funding acquisition: G.I.

**Funding**
This research was funded by the Italian Ministry of Health (Ricerca Corrente, Linea 1) and by Esselunga S.p.A., through a generous liberal donation funding COVID-19 research (issue n. 88/2021).

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to G.I.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

**INMI COVID-19 Vaccine Study Group**

Eleonora Cimini¹, Eleonora Tartaglia¹, Rita Casetti¹, Germana Grassi¹, Flavia Cristofanelli¹, Andrea Capri², Anna Paola Santoro³, Nicoletta Orchi³, Aurora Bettini³, Massimo Francalancia³ & Eliana Specchiarello¹